INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 178 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2020. The put-call ratio across all filers is 0.84 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,328,295 | -17.7% | 25,500 | 0.0% | 0.75% | -16.0% |
| Q2 2023 | $1,614,660 | +16.9% | 25,500 | 0.0% | 0.90% | -6.0% |
| Q1 2023 | $1,380,825 | +247.9% | 25,500 | +240.0% | 0.95% | +143.1% |
| Q4 2022 | $396,900 | +166.4% | 7,500 | +87.5% | 0.39% | +931.6% |
| Q3 2021 | $149,000 | -27.0% | 4,000 | -20.0% | 0.04% | -30.9% |
| Q2 2021 | $204,000 | -14.3% | 5,000 | -28.6% | 0.06% | -31.2% |
| Q1 2021 | $238,000 | -6.3% | 7,000 | -12.5% | 0.08% | -24.5% |
| Q4 2020 | $254,000 | +1714.3% | 8,000 | +1354.5% | 0.11% | +1414.3% |
| Q3 2020 | $14,000 | – | 550 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |